Optic nerve sheath diameter and blood angiogenic markers in pre-eclampsia
Optic Nerve Sheath Measurement and Angiogenic Factors for the Diagnosis of Pre-eclampsia
We will test whether ultrasound measurements of the optic nerve sheath together with blood angiogenic factor levels can help predict complications in pregnant women with pre-eclampsia between 24 and 40 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Saint Thomas Hospital, Panama Academic / other |
| Locations | 1 site (Panama City, Provincia de Panamá) |
| Trial ID | NCT06122220 on ClinicalTrials.gov |
What this trial studies
This study will measure optic nerve sheath diameter (ONSD) by ultrasound and collect blood to measure angiogenic factors in pregnant women diagnosed with pre-eclampsia. Investigators will correlate ONSD values with serum angiogenic marker levels and clinical outcomes to determine predictive ability for adverse maternal or fetal events. Eligible participants are pregnant women between 24 and 40 weeks of gestation without multiple gestation or major comorbidities such as chronic renal disease, significant cardiac disease, neurological disorders, or certain hematologic conditions. The study is conducted at Saint Thomas Hospital in Panama City and uses these combined noninvasive measurements to refine risk stratification in pre-eclampsia.
Who should consider this trial
Good fit: Ideal candidates are pregnant women with a diagnosis of pre-eclampsia between 24 and 40 weeks of gestation who do not meet the exclusion criteria listed by the study.
Not a fit: Women with multiple gestation, significant preexisting neurological, renal or cardiac disease, a history of three or more cesarean sections, or outside the 24–40 week window are unlikely to be eligible or to benefit from this protocol.
Why it matters
Potential benefit: If successful, the combined use of ONSD and angiogenic markers could help clinicians identify women at high risk of complications and guide timing of delivery to improve maternal and neonatal outcomes.
How similar studies have performed: Previous research has shown angiogenic factor levels predict severity and outcomes in pre-eclampsia and that ONSD can reflect raised intracranial pressure, but combining ONSD and angiogenic markers for outcome prediction is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant women between 24 and 40 weeks of gestation. Exclusion Criteria: * Multiple gestation * Maternal vasculitis * Previous cesarean section (3 or more) * Brain or eye tumors * Neurological conditions * Chronic renal disease * Purpura * Heart disease
Where this trial is running
Panama City, Provincia de Panamá
- Saint Thomas Hospital — Panama City, Provincia de Panamá, Panama (Recruiting)
Study contacts
- Study coordinator: Osvaldo Reyes, MD
- Email: oreyespanama@yahoo.es
- Phone: +507 65655041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.